What is the dosage of Tarlatamab-Imdelltra?

Tarlatamab-Imdelltra is a new bispecific T-cell ligation antibody (BiTE) that mainly targets DLL3-expressing tumor cells and is used to treat refractory malignant tumors such as small cell lung cancer (ES-SCLC). As an immunotherapy drug, its administration method is different from traditional chemotherapy or targeted drugs. It needs to be intravenously infused in a strict medical environment and combined with other drugs to reduce side effects. Imdelltra is usually treated in a 28-day cycle, with the recommended ascending dose regimen, combined with dexamethasone, intravenous fluid rehydration and other measures to reduce the risk of cytokine release syndrome (CRS).

In the first treatment cycle (Cycle 1), a smaller dose of 1 mg is given on day 1 to help the patient gradually adapt to the drug; on days 8 and 15, a full therapeutic dose of 10 mg is infused. Before the infusion on days 1 and 8, doctors will intravenously inject 8 mg of dexamethasone within 1 hour to prevent acute reactions such as CRS; at the same time, 1 liter of normal saline will be added within 4 to 5 hours after the infusion is completed to reduce immune-related side effects. In subsequent cycles 2 to 4, the drug dose was fixed at 10 mg and was infused on days 1 and 15 of each cycle. During the fifth cycle and beyond, the biweekly dosing regimen was maintained until disease progression or unacceptable toxicity.

This strict dose escalation and combined drug regimen not only reflectsImdelltra’s clinical safety management requirements, but also illustrates its significant differences as an immunotherapy drug and traditional chemotherapy. As more and more research data on DLL3 targets accumulate, the application prospects of Tarlatamab in patients with drug-resistant small cell lung cancer have received widespread attention. For clinicians, mastering standardized medication regimens and monitoring measures is the key to ensuring that patient benefits and risks are controllable.

Reference materials:https://www.drugs.com/mtm/tarlatamab.html